Alzheimer's Research & Therapy | Most Viewed

Submit a manuscript Register Contact us Follow us on Twitter

Explore journal

Advertisement

Articles

Display/download options Articles per page: 25 | 50 | 100

Display options

Editor's summary Citation

Download options

Send
To

	All
	76. 2543 Accesses	Research ¹⁸F-florbetaben Aβ imaging in mild cognitive impairment Kevin Ong, Victor L Villemagne, Alex Bahar-Fuchs, Fiona Lamb, Gaël Chételat, Parnesh Raniga, Rachel S Mulligan, Olivier Salvado, Barbara Putz, Katrin Roth, Colin L Masters, Cornelia B Reininger, Christopher C Rowe Alzheimer's Research & Therapy 2013, 5:4 (16 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Higher levels of amyloid-β deposition, measured using 18F-florbetaben imaging, was associated with more severe memory loss in mild cognitive impairment (MCI) patients, proving its utility in early MCI diagnosis.
	77. 2540 Accesses	Review Vascular risk factors and Alzheimer's disease: are these risk factors for plaques and tangles or for concomitant vascular pathology that increases the likelihood of dementia? An evidence-based review Helena C Chui, Ling Zheng, Bruce R Reed, Harry V Vinters, Wendy J Mack Alzheimer's Research & Therapy 2011, 4:1 (4 January 2012) Abstract \| Full text \| PDF \| Editor’s summary Current studies fail to show a positive association between vascular risk factors and an increase in Alzheimer's disease (AD) pathology, as discussed in an evidence-based review by Chui and colleagues.
	78. 2531 Accesses	Review Should EOAD patients be included in clinical trials? Kinga Szigeti, Rachelle S Doody Alzheimer's Research & Therapy 2011, 3:4 (8 February 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Szigeti and Doody suggest that enrolling early-onset Alzheimer’s (EOAD) disease patients in clinical trials would help to detect a signal of efficacy, especially for amyloid-based therapies.
	79. 2518 Accesses	Review Relationships between the amyloid precursor protein and its various proteolytic fragments and neuronal systems Sally Hunter, Carol Brayne Alzheimer's Research & Therapy 2012, 4:10 (13 April 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Hunter and Brayne build a map, modelling relationships between the amyloid precursor protein (APP) and its proteolytic fragments with other neuronal systems and discussing alternative perspectives for its role in Alzheimer's disease progression.
	80. 2462 Accesses	Review Amyloid imaging and memory change for prediction of cognitive impairment Susan M Resnick, Jitka Sojkova Alzheimer's Research & Therapy 2011, 3:3 (31 January 2011) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central
	81. 2462 Accesses	Research Factors that influence survival in a probable Alzheimer disease cohort Susan D Rountree, Wenyaw Chan, Valory N Pavlik, Eveleen J Darby, Rachelle S Doody Alzheimer's Research & Therapy 2012, 4:16 (15 May 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Multiple factors influence survival in a large Alzheimer's disease (AD) cohort and the rate of cognitive decline at the initial patient visit is an important mortality predictor.
	82. 2442 Accesses	Commentary Amyloid imaging in prodromal Alzheimer's disease Rik Ossenkoppele, Bart NM van Berckel, Niels D Prins Alzheimer's Research & Therapy 2011, 3:26 (19 September 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Ossenkoppele and colleagues discuss a new study demonstrating that, due to a gradual increase in amyloid deposition, amyloid imaging can predict clinical progression to Alzheimer's disease (AD) in patients with mild cognitive impairment.
	83. 2439 Accesses	Viewpoint Con: Can biomarkers be gold standards in Alzheimer's disease? Kenneth Rockwood Alzheimer's Research & Therapy 2010, 2:16 (25 June 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Rockwood argues that we should employ a number of clinical measures, such as neuropsychological tests and clinical interviews, rather than relying solely on biomarkers to predict Alzheimer’s disease outcome.
	84. 2385 Accesses	Commentary From model system to clinical medicine: pathophysiologic links of common proteinopathies Pamela J McMillan, James B Leverenz Alzheimers Res Ther 2010, 2:26 (17 September 2010) Abstract \| Full text \| PDF \| PubMed
	85. 2377 Accesses	Research Pooled-DNA sequencing identifies novel causative variants in PSEN1, GRN and MAPT in a clinical early-onset and familial Alzheimer's disease Ibero-American cohort Sheng Jin, Pau Pastor, Breanna Cooper, Sebastian Cervantes, Bruno A Benitez, Cristina Razquin, Alison Goate, Ibero-American Alzheimer Disease Genetics Group Researchers, Carlos Cruchaga Alzheimer's Research & Therapy 2012, 4:34 (20 August 2012) Abstract \| Full text \| PDF \| PubMed \| F1000 Biology \| Editor’s summary Pooled-DNA sequencing identifies novel GRN and MAPT mutations that match the frequency of APP, PSEN1 and PSEN2 mutations in clinical Alzheimer's disease (AD) cases, suggesting an influence on frontotemporal dementia and AD phenotypes.
	86. 2364 Accesses	Review Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome Benjamin Lam, Mario Masellis, Morris Freedman, Donald T Stuss, Sandra E Black Alzheimer's Research & Therapy 2013, 5:1 (9 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Lam and colleagues review the different subtypes of Alzheimer's disease (AD), discussing the need for personalized AD medicine and the potential for targeting specific AD subtypes in future clinical trials.
	87. 2337 Accesses	Correction Correction: Predicting progression of Alzheimer's disease Rachelle S Doody, Valory Pavlik, Paul Massman, Susan Rountree, Eveleen Darby, Wenyaw Chan Alzheimer's Research & Therapy 2010, 2:14 (18 May 2010) Full text \| PDF \| PubMed
	88. 2317 Accesses	Review Whether, when and how chronic inflammation increases the risk of developing late-onset Alzheimer's disease Piet Eikelenboom, Jeroen JM Hoozemans, Rob Veerhuis, Eric van Exel, Annemieke JM Rozemuller, Willem A van Gool Alzheimer's Research & Therapy 2012, 4:15 (4 June 2012) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Eikelenboom and colleagues discuss how clinical studies that show peripheral inflammation increases dementia risk and accelerates the rate of deterioration in demented patients can provide scope for Alzheimer's disease (AD) prevention.
	89. 2293 Accesses	Commentary Predicting Alzheimer's risk: why and how? Deborah E Barnes, Sei J Lee Alzheimer's Research & Therapy 2011, 3:33 (25 November 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary In light of recent research, Barnes and Lee consider the current limitations and future directions in identifying individuals at increased risk of developing symptomatic Alzheimer's disease (AD).
	90. 2284 Accesses	Research Age-related increase in amyloid plaque burden is associated with impairment in conditioned fear memory in CRND8 mouse model of amyloidosis Amanda Hanna, Kayleigh Iremonger, Pritam Das, Dennis Dickson, Todd Golde, Christopher Janus Alzheimer's Research & Therapy 2012, 4:21 (14 June 2012) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary An increase in amyloid β (Aβ) burden in transgenic mice correlates with progressive impairment in fear conditioned memory, indicating a therapeutic potential for memory improvement in mouse models of amyloidosis.
	91. 2282 Accesses	Research Longitudinal neuroimaging and neuropsychological profiles of frontotemporal dementia with C9ORF72 expansions Colin J Mahoney, Laura E Downey, Gerard R Ridgway, Jon Beck, Shona Clegg, Melanie Blair, Sarah Finnegan, Kelvin K Leung, Tom Yeatman, Hannah Golden, Simon Mead, Jonathan D Rohrer, Nick C Fox, Jason D Warren Alzheimer's Research & Therapy 2012, 4:41 (24 September 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Longitudinal neuropsychological and neuroimaging data on a cohort of patients with pathological repeat expansions in C9ORF72 is assessed, demonstrating longitudinal biomarkers for tracking the evolution of the C9ORF72 mutation phenotype.
	92. 2277 Accesses	Commentary What was lost in translation in the DHA trial is whom you should intend to treat Sally A Frautschy, Greg M Cole Alzheimer's Research & Therapy 2011, 3:2 (20 January 2011) Abstract \| Full text \| PDF \| PubMed
	93. 2224 Accesses	Review Examining the mechanisms that link β-amyloid and α-synuclein pathologies Samuel E Marsh, Mathew Blurton-Jones Alzheimer's Research & Therapy 2012, 4:11 (30 April 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Marsh and Blurton-Jones review evidence suggesting β-amyloid (Aβ) and α-synuclein (α-syn) interact synergistically to enhance aggregation and accelerate cognitive decline, and propose potential mechanistic links between Aβ and α-syn pathologies.
	94. 2173 Accesses	Review Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease Sascha Weggen, Dirk Beher Alzheimer's Research & Therapy 2012, 4:9 (30 March 2012) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary The molecular consequences of amyloid precursor protein and presenilin gene mutations in familial Alzheimer's disease (FAD) are examined by Weggen and Beher; in view of potential therapeutic treatments directed at amyloid-beta peptides.
	95. 2158 Accesses	Commentary Dementia: a global health priority - highlights from an ADI and World Health Organization report Marc Wortmann Alzheimer's Research & Therapy 2012, 4:40 (21 September 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Marc Wortmann, Executive Director of Alzheimer's Disease International, provides a special commentary explaining the importance of World Alzheimer Reports and the need to create national Alzheimer Plans to provide frameworks for action.
	96. 2139 Accesses	Review What can we learn from study of Alzheimer's disease in patients with Down syndrome for early-onset Alzheimer's disease in the general population? Robyn A Wallace, Arthur J Dalton Alzheimer's Research & Therapy 2011, 3:13 (19 April 2011) Abstract \| Full text \| PDF \| PubMed
	97. 2126 Accesses	Review Genetic counseling for FTD/ALS caused by the C9ORF72 hexanucleotide expansion Jamie C Fong, Anna M Karydas, Jill S Goldman Alzheimer's Research & Therapy 2012, 4:27 (19 July 2012) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Fong and colleagues discuss the genetic counselling considerations for individuals and their families considering genetic testing for the pathogenic C9ORF72 hexanucleotide expansion in familial frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
	98. 2124 Accesses	Review Does a prion-like mechanism play a major role in the apparent spread of α-synuclein pathology? Amanda N Sacino, Benoit I Giasson Alzheimer's Research & Therapy 2012, 4:48 (17 December 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Sacino and Giasson review evidence that a self-promoting prion-like mechanism may contribute to the spread and progression of alpha-synuclein pathology in Parkinson’s disease and other synucleinopathies, calling for further study.
	99. 2115 Accesses	Review Technical aspects of amyloid imaging for Alzheimer's disease Paul Edison, Rainer Hinz, David J Brooks Alzheimer's Research & Therapy 2011, 3:25 (31 August 2011) Abstract \| Full text \| PDF \| PubMed
	100. 2106 Accesses	Review Progranulin axis and recent developments in frontotemporal lobar degeneration Alexandra M Nicholson, Jennifer Gass, Leonard Petrucelli, Rosa Rademakers Alzheimer's Research & Therapy 2012, 4:4 (23 January 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Recent data involving progranulin protein (PGRN) biology and frontotemporal lobar degeneration (FTLD), and the necessity of further elucidation of PGRN biology in FTLD-related neurodegeneration, is discussed by Nicholson and colleagues.